Abbott Laboratories (ABT) stock
ABTNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 14/3034% above fair value
$104.71−2.74 (-2.55%)
Close on Nov 17, 2026Market cap $181.19BP/E 33.7Yield 2.29%
Abbott Laboratories total assets
Total assets on the balance sheet at the end of each period.
Abbott Laboratories's total assets was $109.22B at Jun 30, 2026. For fiscal 2025 it was $86.71B, up 6.5% from the year before. Over ten years it grew 7.7% a year on average. The highest annual figure on record is $86.71B in fiscal 2025.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $86.71B | +6.5% |
| FY2024 | Dec 31, 2024 | $81.41B | +11.2% |
| FY2023 | Dec 31, 2023 | $73.21B | -1.6% |
| FY2022 | Dec 31, 2022 | $74.44B | -1.0% |
| FY2021 | Dec 31, 2021 | $75.20B | +3.6% |
| FY2020 | Dec 31, 2020 | $72.55B | +6.9% |
| FY2019 | Dec 31, 2019 | $67.89B | +1.1% |
| FY2018 | Dec 31, 2018 | $67.17B | -11.9% |
| FY2017 | Dec 31, 2017 | $76.25B | +44.8% |
| FY2016 | Dec 31, 2016 | $52.67B | +27.7% |
| FY2015 | Dec 31, 2015 | $41.25B | +0.1% |
| FY2014 | Dec 31, 2014 | $41.21B | -4.0% |
| FY2013 | Dec 31, 2013 | $42.94B | -36.1% |
| FY2012 | Dec 31, 2012 | $67.24B | +11.5% |
| FY2011 | Dec 31, 2011 | $60.28B | -0.5% |
| FY2010 | Dec 31, 2010 | $60.57B | +15.2% |
| FY2009 | Dec 31, 2009 | $52.58B | +24.0% |
| FY2008 | Dec 31, 2008 | $42.42B | +6.8% |
| FY2007 | Dec 31, 2007 | $39.71B | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $109.22B | +30.0% |
| Q1 FY2026 | Mar 31, 2026 | $110.43B | +35.6% |
| Q4 FY2025 | Dec 31, 2025 | $86.71B | +6.5% |
| Q3 FY2025 | Sep 30, 2025 | $84.18B | +13.2% |
| Q2 FY2025 | Jun 30, 2025 | $84.00B | +15.0% |
| Q1 FY2025 | Mar 31, 2025 | $81.45B | +12.4% |
| Q4 FY2024 | Dec 31, 2024 | $81.41B | +11.2% |
| Q3 FY2024 | Sep 30, 2024 | $74.36B | +3.1% |
| Q2 FY2024 | Jun 30, 2024 | $73.02B | -0.5% |
| Q1 FY2024 | Mar 31, 2024 | $72.47B | -1.8% |
| Q4 FY2023 | Dec 31, 2023 | $73.21B | -1.6% |
| Q3 FY2023 | Sep 30, 2023 | $72.09B | -1.0% |
| Q2 FY2023 | Jun 30, 2023 | $73.35B | -1.1% |
| Q1 FY2023 | Mar 31, 2023 | $73.79B | -0.3% |
| Q4 FY2022 | Dec 31, 2022 | $74.44B | -1.0% |
| Q3 FY2022 | Sep 30, 2022 | $72.80B | -1.3% |
| Q2 FY2022 | Jun 30, 2022 | $74.20B | +1.3% |
| Q1 FY2022 | Mar 31, 2022 | $74.01B | +1.7% |
| Q4 FY2021 | Dec 31, 2021 | $75.20B | +3.6% |
| Q3 FY2021 | Sep 30, 2021 | $73.80B | +6.9% |
| Q2 FY2021 | Jun 30, 2021 | $73.27B | +6.5% |
| Q1 FY2021 | Mar 31, 2021 | $72.79B | +9.0% |
| Q4 FY2020 | Dec 31, 2020 | $72.55B | +6.9% |
| Q3 FY2020 | Sep 30, 2020 | $69.04B | +0.7% |
| Q2 FY2020 | Jun 30, 2020 | $68.78B | +0.5% |
| Q1 FY2020 | Mar 31, 2020 | $66.78B | -1.2% |
| Q4 FY2019 | Dec 31, 2019 | $67.89B | +1.1% |
| Q3 FY2019 | Sep 30, 2019 | $68.54B | -4.3% |
| Q2 FY2019 | Jun 30, 2019 | $68.43B | +0.0% |
| Q1 FY2019 | Mar 31, 2019 | $67.61B | -4.7% |
| Q4 FY2018 | Dec 31, 2018 | $67.17B | -11.9% |
| Q3 FY2018 | Sep 30, 2018 | $71.64B | -0.8% |
| Q2 FY2018 | Jun 30, 2018 | $68.42B | -3.8% |
| Q1 FY2018 | Mar 31, 2018 | $70.91B | +0.0% |
| Q4 FY2017 | Dec 31, 2017 | $76.25B | +44.8% |
| Q3 FY2017 | Sep 30, 2017 | $72.25B | +82.9% |
| Q2 FY2017 | Jun 30, 2017 | $71.15B | – |
| Q1 FY2017 | Mar 31, 2017 | $70.89B | – |
| Q4 FY2016 | Dec 31, 2016 | $52.67B | – |
| Q3 FY2016 | Sep 30, 2016 | $39.50B | – |
See a number that looks wrong?